CO6351781A2 - Derivados de isoquinolinona como antagonistas de nk3 - Google Patents

Derivados de isoquinolinona como antagonistas de nk3

Info

Publication number
CO6351781A2
CO6351781A2 CO11026657A CO11026657A CO6351781A2 CO 6351781 A2 CO6351781 A2 CO 6351781A2 CO 11026657 A CO11026657 A CO 11026657A CO 11026657 A CO11026657 A CO 11026657A CO 6351781 A2 CO6351781 A2 CO 6351781A2
Authority
CO
Colombia
Prior art keywords
alkyl
alkynyl
alkenyl
ring
atoms
Prior art date
Application number
CO11026657A
Other languages
English (en)
Inventor
Nikolay Khanzhin
Karsten Juhl
Klaus Baek Simonsen
Soren Moller Nielsen
Original Assignee
H Lundbeck & Co As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41227186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6351781(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck & Co As filed Critical H Lundbeck & Co As
Publication of CO6351781A2 publication Critical patent/CO6351781A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Un compuesto de acuerdo con la fórmula Ien donde A representa N, CH o CR1; cada R1 representa independientemente hidrógeno, alquiloC1-6, alqueniloC2-6, alquiniloC2-6, -C(O)-alquiloC1-6, -C(O)-alqueniloC2-6, -C(O)- alquiniloC2-6, -C(O)-O-alquiloC1-6, -C(O)-O-alqueniloC2-6, -C(O)-O-alquiniloC2-6 o fenilo, en donde dicho fenilo, alquiloC1-6, alqueniloC2-6 o alquiniloC2-6 está opcionalmente sustituido con uno o más sustituyentes seleccionados de halógeno, hidroxilo, haloalquiloC1-6, nitro, alcoxiC1-6 y NR2R3; X representa hidrógeno, alquiloC1-6 opcionalmente sustituido con F, o - CRaRb-X', en donde X' representa un grupo funcional monocíclico saturado que tiene 5-6 átomos en el anillo, uno de los cuales es N, y en donde uno o dos átomos en el anillo adicionales pueden ser un heteroátomo seleccionado de N, O y S, donde el anillo monocíclico puede estar sustituido con uno o más sustituyentes W, en donde W se selecciona de alquiloC1-6, alqueniloC2-6, alquiniloC2-6, haloalquiloC1-6 o (=O); Ra y Rb, cada uno individualmente, representa hidrógeno, -CH3 o halógeno; Q representa un enlace, -CH2-, -NH- o -O-; Y representa alquiloC1-6, aIqueniloC2-6 o alquiniloC2-6, en donde dicho alquilo, alquenilo o alquinilo puede estar sustituido con uno o más sustituyentes P, en donde P se selecciona de halógeno, hidroxi, alcoxiC1-6, ciano, -S-alquiloC1-6 y un grupo funcional monocíclico saturado que tiene 5-6 átomos en el anillo, en donde uno de los átomos en el anillo puede ser N y el resto es C; o Y puede representar un grupo funcional monocíclico saturado que tiene 4-6 átomos en el anillo, en donde uno de dichos átomos en el anillo se puede seleccionar de N y O, siendo el resto C, y donde dicho grupo funcional monocíclico saturado puede estar sustituido con uno o más sustituyentes Z, en donde Z se selecciona de alquiloC1-6, alqueniIoC2-6, alquiniloC2-6, (=O), C(O)H, -C(O)-alquiloC1-6, halógeno, alcoxiC1-6,<hidroxialquiloC1-6 e hidroxi; en donde cada uno de R2 y R3 representa independientemente hidr¢geno, alquiloC1-6, alqueniloC2-6, alquiniloC2-6, hidroxialquiloC1-6 o haloalquiloC1-6; cada uno de R4-R8 y R9-R12 representa independientemente hidr¢geno, alquiloC1-6, alqueniloC2-6, alquiniloC2-6, hal¢geno, NR2R3, hidroxi, ciano, nitro, alcoxiC1-6, haloalquiloC1-6 o hidroxialquiloC1-6; siempre y cuando dicho compuesto sea diferente de (1-fenil-etil)-amida de  cido 2-metil-1-oxo-1,2-dihidro-isoquinolin-4-carbox¡lico; y sales farmacéuticamente aceptables de dichos compuestos. Este compuesto es usado en terapia, en particular en el tratamiento de la psicosis.
CO11026657A 2008-09-15 2011-03-04 Derivados de isoquinolinona como antagonistas de nk3 CO6351781A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200801290 2008-09-15
DKPA200900010 2009-01-06

Publications (1)

Publication Number Publication Date
CO6351781A2 true CO6351781A2 (es) 2011-12-20

Family

ID=41227186

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11026657A CO6351781A2 (es) 2008-09-15 2011-03-04 Derivados de isoquinolinona como antagonistas de nk3

Country Status (27)

Country Link
EP (1) EP2342182B1 (es)
JP (1) JP5536776B2 (es)
KR (1) KR101638641B1 (es)
CN (1) CN102149685B (es)
AR (1) AR073511A1 (es)
AU (1) AU2009291309B2 (es)
BR (1) BRPI0917245B8 (es)
CA (1) CA2732612C (es)
CL (1) CL2011000533A1 (es)
CO (1) CO6351781A2 (es)
CY (1) CY1113743T1 (es)
DK (1) DK2342182T3 (es)
EA (1) EA021581B1 (es)
ES (1) ES2399177T3 (es)
HR (1) HRP20130038T1 (es)
IL (1) IL210236A (es)
MX (1) MX2011001786A (es)
MY (1) MY164998A (es)
NZ (1) NZ591265A (es)
PL (1) PL2342182T3 (es)
PT (1) PT2342182E (es)
RS (1) RS52674B (es)
SI (1) SI2342182T1 (es)
SM (1) SMT201300020B (es)
TW (1) TWI454461B (es)
WO (1) WO2010028655A1 (es)
ZA (1) ZA201103119B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008131779A1 (en) 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
EA201170074A1 (ru) 2008-06-23 2011-10-31 Х. Лундбекк А/С Изохинолиноновые производные в качестве антагонистов nk3
MX2011004034A (es) 2008-10-20 2011-05-10 Lundbeck & Co As H Derivados de isoquinolinona como antagonistas de nk3.
TW201143768A (en) 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
TW201144311A (en) * 2010-03-12 2011-12-16 Lundbeck & Co As H Azaisoquionolinone derivatives as NK3 antagonists
CN104203919A (zh) 2011-11-09 2014-12-10 艾伯维德国有限责任两合公司 可用作10a型磷酸二酯酶的抑制剂的杂环甲酰胺类
CA3098603A1 (en) * 2018-04-27 2019-10-31 Sojournix, Inc. Polymorphic and amorphous forms of isoquinolinone and methods of use thereof
WO2023152888A1 (ja) * 2022-02-10 2023-08-17 カルナバイオサイエンス株式会社 フルオロイソキノリン化合物およびその製造法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9825554D0 (en) * 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
JP2004525183A (ja) * 2001-04-11 2004-08-19 グラクソスミスクライン・ソシエタ・ペル・アチオニ Nk−3およびnk−2受容体アンタゴニストとしてのキノリン−4−カルボキサミド誘導体
GB0509405D0 (en) * 2005-05-10 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
WO2008131779A1 (en) * 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists

Also Published As

Publication number Publication date
BRPI0917245A2 (pt) 2015-11-10
AR073511A1 (es) 2010-11-10
AU2009291309B2 (en) 2014-07-17
EA021581B1 (ru) 2015-07-30
SI2342182T1 (sl) 2013-04-30
CA2732612C (en) 2016-08-09
CN102149685A (zh) 2011-08-10
IL210236A (en) 2013-08-29
TW201010979A (en) 2010-03-16
NZ591265A (en) 2013-02-22
EP2342182B1 (en) 2012-11-14
ES2399177T3 (es) 2013-03-26
JP2012502069A (ja) 2012-01-26
MX2011001786A (es) 2011-03-29
RS52674B (en) 2013-06-28
PL2342182T3 (pl) 2013-04-30
WO2010028655A1 (en) 2010-03-18
JP5536776B2 (ja) 2014-07-02
MY164998A (en) 2018-02-28
BRPI0917245B1 (pt) 2020-07-28
CY1113743T1 (el) 2016-06-22
IL210236A0 (en) 2011-03-31
CL2011000533A1 (es) 2011-08-26
BRPI0917245A8 (pt) 2018-08-14
EP2342182A1 (en) 2011-07-13
KR20110059849A (ko) 2011-06-07
TWI454461B (zh) 2014-10-01
ZA201103119B (en) 2012-09-26
CA2732612A1 (en) 2010-03-18
EA201170447A1 (ru) 2011-08-30
CN102149685B (zh) 2015-01-07
HRP20130038T1 (hr) 2013-02-28
AU2009291309A1 (en) 2010-03-18
PT2342182E (pt) 2013-02-11
KR101638641B1 (ko) 2016-07-11
DK2342182T3 (da) 2013-02-04
SMT201300020B (it) 2013-05-06
BRPI0917245B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
CO6351781A2 (es) Derivados de isoquinolinona como antagonistas de nk3
CL2020001919A1 (es) Inhibidores de endonucleasa cap-dependientes.
AR060591A1 (es) Compuestos imidazo
AR072198A1 (es) Derivados de isoquinolinona como antagonistas de nk3 y composiciones farmaceuticas que los contienen
AR060590A1 (es) Compuestos imidazo
AR047538A1 (es) Piridazinonas como antagonistas de las integrinas alfa4
PE20091429A1 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas como inhibidores de la elastasa neutrofila humana (hne)
PE20080841A1 (es) Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion
ECSP11010830A (es) Derivados de heteroarilo como inhibidores de dgat1
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
AR061603A1 (es) Derivados de etenilcarboxamidas microbicidas
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
AR054799A1 (es) Derivados de oxindol
AR073891A1 (es) Derivados de isoquinolinona antagonistas de receptores nk3, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de psicosis, alzheimer y otras enfermedades.
AR079497A1 (es) Derivados fenilimidazol que comprenden un enlazante de etinileno como inhibidores de enzima pde10a
UY32475A (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmacéuticas que los contienen
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
AR060813A1 (es) Moduladores de mglur5 iii
AR059094A1 (es) Derivados de ciclohexil - sulfonamida
ECSP099351A (es) Compuestos heterociclicos y su uso como inhibidores de la
AR068376A1 (es) Amidas heterociclicas utiles para inhibir la via hedgehog.
AR069607A1 (es) Inhibidores de la estearoil-coa desaturasa
AR060652A1 (es) Moduladores de receptor glutamato metabotropico subtipo 5 (mglur5 ii)
AR055666A1 (es) Inhibidores inntr

Legal Events

Date Code Title Description
FC Application refused